Raymond James Upgrades Alpha Cognition (NASDAQ:ACOG) to Moderate Buy

Raymond James upgraded shares of Alpha Cognition (NASDAQ:ACOG) to a moderate buy rating in a report published on Tuesday,Zacks.com reports.

Separately, HC Wainwright began coverage on Alpha Cognition in a research note on Tuesday, March 18th. They issued a “buy” rating and a $20.00 price target for the company.

Alpha Cognition Stock Up 0.7 %

Shares of Alpha Cognition stock opened at $5.52 on Tuesday. The business has a 50-day simple moving average of $5.87. Alpha Cognition has a twelve month low of $4.66 and a twelve month high of $7.00. The firm has a market cap of $88.43 million, a PE ratio of -2.16 and a beta of 2.50.

Institutional Investors Weigh In On Alpha Cognition

Several institutional investors and hedge funds have recently bought and sold shares of ACOG. National Bank of Canada FI bought a new position in Alpha Cognition in the 4th quarter valued at about $69,000. Manatuck Hill Partners LLC bought a new stake in shares of Alpha Cognition during the 4th quarter worth approximately $395,000. Tudor Investment Corp ET AL acquired a new stake in shares of Alpha Cognition during the 4th quarter worth approximately $412,000. MYDA Advisors LLC acquired a new stake in shares of Alpha Cognition in the 4th quarter valued at $589,000. Finally, Bleichroeder LP bought a new position in shares of Alpha Cognition in the fourth quarter worth about $1,024,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.